Unique ID issued by UMIN | UMIN000031388 |
---|---|
Receipt number | R000034119 |
Scientific Title | Pilot study of neoadjuvant chemotherapy with S-1 and oxaliplatin clinical Stage III gastric cancer |
Date of disclosure of the study information | 2018/02/20 |
Last modified on | 2018/02/20 16:08:34 |
Pilot study of neoadjuvant chemotherapy with S-1 and oxaliplatin clinical Stage III gastric cancer
Pilot study of neoadjuvant chemotherapy with S-1/oxaliplatin in clinical Stage III gastric cancer
Pilot study of neoadjuvant chemotherapy with S-1 and oxaliplatin clinical Stage III gastric cancer
Pilot study of neoadjuvant chemotherapy with S-1/oxaliplatin in clinical Stage III gastric cancer
Japan |
Gastric cancer
Gastrointestinal surgery |
Malignancy
NO
To evaluate the efficacy and safety of S-1 and oxaliplatin as neoadjuvant chemotherapy for the clinical Stage III gastric cancer
Safety,Efficacy
Exploratory
Pragmatic
Response rate
Completion rate of neoadjuvant chemotherapy
Completion rate of adjuvant chemotherapy
Pathological response rate
Incidence of adverse events of neoadjuvant chemotherapy
Incidence of postoperative complications
R0 resection rate
Progression-free survival
Overall survival
Completion rate of laparoscopic surgery
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Maneuver |
S-1:80-120mg/body/day,PO,day1-14,
Oxaliplatin:130 mg/m2, IV day1, every 21 days for 2 cycles followed by D2 surgery
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically proven gastric
adenocarcinoma
2) Clinical Stage III gastric cancer
3) Age above 20 years old
4) ECOG performance status of 0 or 1
5) No previous chemotherapy,radiation
therapy or surgery for gastric cancer
6) Adequate organ function
1. WBC:>=3,000/mm3,<12,000/mm3
2. Neutrophil:>=1,500/mm3
3. Platelet:>=100,000/mm3
4. Hemoglobin:>=9.0g/dL
5. AST(GOT)/ALT(GPT):<=100 IU/L
6. Total bilirubin:<=2.0mg/dL
7. Serum creatinine:<=1.2mg
8. Creatinine clearance:>=60 mL/min
7) Possible oral intake
8) Written informed consent from patient
1) With active double or multiple cancers
2) Severe complications
3) With active infection
4) Past history of severe hypersensitivity to drugs
5) Under treatment with flucytosine
6) Under treatment with warfarin
7) Pregnant women, or women with the
possibility of the pregnancy, Men who want let to pregnancy
8) Patients judged inappropriate for the study by the physicians
20
1st name | |
Middle name | |
Last name | Sayuri Konishi |
Kyoto Katsura Hospital
Department of Surgery, Gastro-Intestinal Center
17 Yamadahirao-cho, Nishikyo-ku, Kyoto, 615-8256, Japan
075-391-5811
d_manaka@katsura.com
1st name | |
Middle name | |
Last name | Sayuri Konishi |
Kyoto Katsura Hospital
Department of Surgery, Gastro-Intestinal Center
Yamadahirao-cho, Nishikyo-ku, Kyoto, 615-8256, Japan
075-391-5811
sayurik0713@gmail.com
Kyoto Katsura Hospital
none
Self funding
NO
2018 | Year | 02 | Month | 20 | Day |
Unpublished
No longer recruiting
2016 | Year | 02 | Month | 01 | Day |
2016 | Year | 02 | Month | 01 | Day |
2018 | Year | 02 | Month | 20 | Day |
2018 | Year | 02 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034119